Nanoparticles as drug delivery systems

Wilczewska, Agnieszka Z.; Niemirowicz, Katarzyna; Markiewicz, Karolina H.; Car, Halina

doi:10.1016/s1734-1140(12)70901-5

Cited by 1,143 publications

(657 citation statements)

References 232 publications

Supporting

Mentioning

635

Contrasting

Unclassified

Order By: Relevance

“…Efficient drug delivery is very essential for enhancing diagnosis, reducing side effects and drug efficacy. Nanoparticles offer a capable approach towards delivering the therapeutic agents to the targeted organs and their use in cancer treatment (Nazir et al 2014;Chen et al 2016;Rosenholm et al 2011;Wilczewska et al 2012;Sahoo et al 2007;Suri et al 2007). Mesoporous silica nanoparticles are considered to be very promising candidate for drug delivery specifically for water-insoluble drug.…”

Section: Introductionmentioning

confidence: 99%

Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro study

et al. 2017

View full text Add to dashboard Cite

Monastrol is a simple low molecular weight dihydropyrimidine-based kinesin Eg5 inhibitor. Its low cellular activity and its non-drug-like properties have impeded its further development. In a previous report, we have reported various topological parameters to improve the pharmacokinetic properties of monastrol. The purpose of this study is to determine the loading and release feasibility of poorly water-soluble monastrol into the synthesized mesoporous silica nanoparticles (MSNs). The synthesis of MSNs was attained by the ammonia-catalysed hydrolysis and condensation of TEOS in ethanol using polysorbate-80 as surfactant. These were characterized by BET surface area and pore size distribution analyses, SEM, XRD, UV and FTIR spectroscopy. The synthesized monastrol was successfully loaded on MSNPs and coated by hydrogels for successful controlled drug delivery. In vitro release studies are done by simple dialysis method.Monastrol-loaded MSNPs were tested on human cervical epithelial malignant carcinoma (HeLa) cell lines for studying their anticancer activity. Our presented system described a reliable method for targeted delivery of monastrol into the cancer cells in vitro.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There is increasing exploration of nano-DDSs including liposomes and polymeric nanoparticles for delivery of therapeutic agents such as small molecule drugs and nucleic acids [47–49]. However, there are several disadvantages to the use of synthetic nanoparticles, such as low biocompatibility, immunoreaction and safety problems [50].…”

Section: Extracellular Vesiclesmentioning

confidence: 99%

Microfluidics‐based on‐a‐chip systems for isolating and analysing extracellular vesicles

Guo

Tao

Dawn

2018

J of Extracellular Vesicle

150

111

View full text Add to dashboard Cite

Extracellular vesicles (EVs), which can be found in almost all body fluids, consist of a lipid bilayer enclosing proteins and nucleic acids from their cells of origin. EVs can transport their cargo to target cells and have therefore emerged as key players in intercellular communication. Their potential as either diagnostic and prognostic biomarkers or therapeutic drug delivery systems (DDSs) has generated considerable interest in recent years. However, conventional methods used to study EVs still have significant limitations including the time-consuming and low throughput techniques required, while at the same time the demand for better research tools is getting stronger and stronger. In the past few years, microfluidics-based technologies have gradually emerged and have come to play an essential role in the isolation, detection and analysis of EVs. Such technologies have several advantages, including low cost, low sample volumes, high throughput and precision. This review summarizes recent advances in microfluidics-based technologies, compares conventional and microfluidics-based technologies, and includes a brief survey of recent progress towards integrated “on-a-chip” systems. In addition, this review also discusses the potential clinical applications of “on-a-chip” systems, including both “liquid biopsies” for personalized medicine and DDS devices for precision medicine, and then anticipates the possible future participation of cloud-based portable disease diagnosis and monitoring systems, possibly with the participation of artificial intelligence (AI).

show abstract

“…7 In controlled drug delivery systems (DDS) the drug can be transported to the site of action, hence, its effect on vital tissues and minimized undesirable side effects. 8 In addition, DDS protects the drug from rapid degradation or clearance and enhances drug concentration in target site; therefore, lower doses of drug are required. 9 Nanoparticles (structures smaller than 100nm) have a great potential as drug carriers.…”

Section: Introductionmentioning

confidence: 99%

Biochemical and histopathological assessment of atorvastatin-loaded nanoemulsion effectiveness in Rats

Balamash

Al-ddyni

2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Atorvastatin (ATV), a lipid lowering agent, has low solubility and poor dissolution affects its oral bioavailability. Nanoemulsion (NE) has been developed to improve the delivery of therapeutic agents. This study was aimed to assess the ability of the NE in enhancing ATV bioavailability and minimizing its side effects in hyperlipidemic rats.Methods: Thirty-five rats divided into seven groups were utilized in this study. Hyperlipidemia was induced by feeding rats high fat diet (HFD) for 3 months. The antihyperlipidemic activity of 10 and 20 mg/kg of ATV loaded in two different delivery systems; nanoemulsion (10% and 20% ATV-LNE) or in water (10% and 20% ATV-sol), were investigated. At the end of the experiment, body weight, serum and plasma biochemical parameters (lipid profile, glucose, insulin, liver and kidney functions, oxidative stress markers were assessed. Liver and kidney were histopathologically examined. The physical characteristics of NE were determined by the Zetasizer (the z-average diameter and zeta potential).Results: 20% ATV-LNE had the smallest nanoparticles (38.12±6.71nm) whereas it had the largest zeta negative potential of -26.8±4.16mV. The serum biochemical results and the histopathological examination revealed that treatment with 20% ATV-LNE improved the lipid profile by significantly increasing HDL and decreasing cholesterol and low-density lipoprotein. Both 10 and 20% ATV-LNE reduced serum glucose level compared to other used formulas.Conclusions: NE formulas have the potential to improve the bioavailability and efficacy of ATV and reduce its side effects.

show abstract

Nanoparticles as drug delivery systems

Cited by 1,143 publications

References 232 publications

Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro study

Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro study

Microfluidics‐based on‐a‐chip systems for isolating and analysing extracellular vesicles

Biochemical and histopathological assessment of atorvastatin-loaded nanoemulsion effectiveness in Rats

Contact Info

Product

Resources

About